Impact of Lurasidone and Other Antipsychotics on Body Weight: Real-World, Retrospective, Comparative Study of 15,323 Adults with Schizophrenia

Purpose: The primary objectives were to describe weight changes following initiation of lurasidone versus other antipsychotics and estimate the risk of clinically relevant ([greater than or equal to]7%) weight changes. Patients and Methods: This retrospective, longitudinal comparative cohort study w...

Full description

Saved in:
Bibliographic Details
Published in:International journal of general medicine 2021-07, Vol.14, p.4081-4094
Main Authors: Pochiero, Ilena, Calisti, Fabrizio, Comandini, Alessandro, Vecchio, Alessandra Del, Costamagna, Isabella, Rosignoli, Maria Teresa, Cattaneo, Agnese, Nunna, Sasikiran, Peduto, Ilaria, Heiman, Franca, Chang, Hsiu-Ching, Chen, Chi-Chang, Correll, Christoph
Format: Article
Language:English
Subjects:
Ambulatory care
Antipsychotic drugs
Antipsychotics
Blood pressure
Body mass index
Body weight
Clinical medicine
Demographics
FDA approval
Health care
Medical records
Medical research
Medicine, Experimental
Mental disorders
Metabolic syndrome
Mortality
Obesity
Original Research
Overweight
Patients
Population
Psychotropic drugs
real world clinical trials
retrospective studies
Schizophrenia
weight gain
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The primary objectives were to describe weight changes following initiation of lurasidone versus other antipsychotics and estimate the risk of clinically relevant ([greater than or equal to]7%) weight changes. Patients and Methods: This retrospective, longitudinal comparative cohort study was based on electronic medical records (EMRs) of United States (US) adult patients with schizophrenia who were prescribed lurasidone or other antipsychotics as monotherapy between 1 April 2013 and 30 June 2019. Results: Overall, the study included 15,323 patients with a diagnosis of schizophrenia; 6.1% of patients received lurasidone, 60.4% received antipsychotics associated with a mediumhigh risk of weight gain (clozapine, olanzapine, quetiapine, risperidone, paliperidone) and 33.5% received antipsychotics with a low risk of weight gain (aripiprazole, first-generation antipsychotics, ziprasidone). Lurasidone was associated with the smallest proportion of patients experiencing clinically relevant weight gain and the greatest proportion of patients with clinically relevant weight loss. The risk of clinically relevant weight gain was numerically higher with all antipsychotics versus lurasidone and was statistically significant for olanzapine (hazard ratio [HR]=1.541; 95% confidence interval [CI]=1.121; 2.119; p=0.0078) versus lurasidone. The likelihood of [greater than or equal to]7% weight loss was significantly greater with lurasidone versus all antipsychotics (p
ISSN:1178-7074
1178-7074
DOI:10.2147/IJGM.S320611